Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:網膜静脈分枝閉塞症に続発した黄斑浮腫に対するアフリベルセプト硝子体内投与の5か月間の成績の報告。対象と方法:発症から3か月以内と推定される網膜静脈分枝閉塞症9例9眼を対象とした。男性4例,女性5眼で,平均年齢は64歳である。全例に黄斑浮腫があった。罹患眼にアフリベルセプト2mgの硝子体注射を行い,経過により追加投与した。視力は対数視力で評価し,光干渉断層計による中心窩厚を計測した。治療開始から5か月間の経過を追った。結果:治療前の平均視力は0.39±0.24,1か月後0.14±0.16で,有意に改善した(p=0.03)。中心窩厚の平均は,治療前420.0±146.3μm,1月後には301.4±48.7μmで,有意に減少した(p=0.0020)。黄斑浮腫の悪化に対し,アフリベルセプトを3か月目に2眼,4か月目に5眼に再投与した。視力と中心窩厚は,経過観察の期間中維持された。結論:網膜静脈分枝閉塞症に続発した黄斑浮腫に対し,アフリベルセプト硝子体内投与により視力が向上し,中心窩厚が減少した。
Abstract. Purpose:To report the short-term effect of intravitreal injection of aflibercept for macular edema secondary to branch retinal vein occlusion(BRVO). Cases and Method:This study was made on 9 eyes of 9 patients with BRVO less than 3 months of presumed duration. The series comprised 4 males and 5 females. The age averaged 64 years. All the affected eyes showed cystoid macular edema(CME)and received intravitreal 2 mg aflibercept. The treatment was repeated when CME recurred. Visual acuity was evaluated as logMAR. Foveal thickness was measured by optical coherence tomography. Cases were followed up for 5 months. Results:Visual acuity averaged 0.39±0.24 before treatment and 0.14±0.16 one month after treatment. The difference was significant(p=0.03). Foveal thickness averaged 420.0±146.3μm before treatment and 301.4±48.7μm one month after treatment. The difference was significant(p=0.0020). Two eyes received another session of aflibercept after 3 months for recurrence of CME. Five eyes were similarly treated after 4 months. Visual acuity and foveal thickness remained stable during the course of observation. Conclusion:Intravitreal injection of aflibercept was followed by improved visual acuity and reduced foveal thickness in eyes with CME secondary to BRVO.
Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.